Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Mayinglong Pharmaceutical Group Co (SHSE:600993) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Mayinglong Pharmaceutical Group Co's Enterprise Value for the quarter that ended in Jun. 2026 was ¥7,062 Mil.
Mayinglong Pharmaceutical Group Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥738 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mayinglong Pharmaceutical Group Co EV-to-EBIT Related Terms
Mayinglong Pharmaceutical Group Co EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mayinglong Pharmaceutical Group Co EV-to-EBIT Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Mayinglong Pharmaceutical Group Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mayinglong Pharmaceutical Group Co EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Mayinglong Pharmaceutical Group Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Mayinglong Pharmaceutical Group Co's EV-to-EBIT falls into.
Mayinglong Pharmaceutical Group Co's current Enterprise Value is ¥7,747 Mil.
Mayinglong Pharmaceutical Group Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥738 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mayinglong Pharmaceutical Group Co (SHSE:600993) has a EV-to-EBIT of 10.50 as of Sep. 01, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Mayinglong Pharmaceutical Group Co and its competitors. This is 31% below median its historical median of 15.24. Over the past decade, Mayinglong Pharmaceutical Group Co's EV-to-EBIT has ranged from 9.70 to 31.86. According to the industry distribution chart, Mayinglong Pharmaceutical Group Co ranks #208 out of 685 companies in the Drug Manufacturers industry, placing it in the top 30.4%.
Is Mayinglong Pharmaceutical Group Co's EV-to-EBIT too high?
Mayinglong Pharmaceutical Group Co's current EV-to-EBIT of 10.50 is 31% below median its 10-year median of 15.24. Over the past 10 years, this metric has ranged from a low of 9.70 to a high of 31.86. The Drug Manufacturers industry median EV-to-EBIT is 16.22. Mayinglong Pharmaceutical Group Co's value of 10.50 is 35.3% below this industry median. Based on the distribution chart, Mayinglong Pharmaceutical Group Co ranks #208 out of 685 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Mayinglong Pharmaceutical Group Co has a GF Score™ of 96/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Mayinglong Pharmaceutical Group Co's EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Mayinglong Pharmaceutical Group Co ranks #208 out of 685 companies for EV-to-EBIT. This puts Mayinglong Pharmaceutical Group Co in the upper half of its industry. The industry median EV-to-EBIT is 16.22. Mayinglong Pharmaceutical Group Co's value of 10.50 is 35.3% below this benchmark. Historically, Mayinglong Pharmaceutical Group Co's own EV-to-EBIT has ranged from 9.70 to 31.86 over the past decade. While the company's 10-year median is 15.24 vs. the industry median of 16.22, Mayinglong Pharmaceutical Group Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 16.22, based on 685 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mayinglong Pharmaceutical Group Co's current EV-to-EBIT of 10.50 is 35.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Mayinglong Pharmaceutical Group Co and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 16.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mayinglong Pharmaceutical Group Co's current EV-to-EBIT is 10.50, which is 31% below median its own 10-year median of 15.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mayinglong Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Mayinglong Pharmaceutical Group Co (SHSE:600993) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥29.30, compared to a current price of ¥23.21 — trading 20.8% below its estimated fair value. The current EV-to-EBIT is 10.50, which is 31% below median its 10-year median of 15.24 and 35.3% below the Drug Manufacturers industry median of 16.22. Mayinglong Pharmaceutical Group Co's overall GF Score™ is 96/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Mayinglong Pharmaceutical Group Co (SHSE:600993), the current EV-to-EBIT is 10.50 as of Sep. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mayinglong Pharmaceutical Group Co (SHSE:600993) Overvalued in 2026?
Based on GuruFocus' analysis, Mayinglong Pharmaceutical Group Co stock appears to be undervalued.
The current stock price of ¥23.21 is trading 20.8% below its estimated GF Value™ of ¥29.30.
GuruFocus considers Mayinglong Pharmaceutical Group Co to be Modestly Undervalued.
Key valuation signals for SHSE:600993:
EV-to-EBIT: 10.50 (31% below median its 10-year median of 15.24)
GF Value™: ¥29.30 vs. price of ¥23.21 (20.8% below fair value)
Industry Position: 35.3% below the Drug Manufacturers median (#208 of 685)
No single metric tells the full story. See the SHSE:600993 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mayinglong Pharmaceutical Group Co Ltd is a China-based company mainly involved in pharmaceutical development, retailing and wholesaling. The company provides ointments, suppositories, and tablets for hemorrhoids.
96GF Score
Get the complete analysis for SHSE:600993
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600993 has been successfully added to your 
